Tweets
#ACR25 Beyond blinatumomab, A-319, CD3xCD19 BiTE in 12 patients with #SLE in China reported dose-dependent depth of B-Cell depletion but not efficacy or safety. One withdrew due to AE. No CRS/ICANS. Be interested to see results in larger trials & longer follow-up @RheumNow https://t.co/e5RuZlFI6i
Links:
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 months 3 weeks ago
In case there was any doubt:
GCA leads to ischemic vision loss
PMR does not
#ACR25 ABST0753 @RheumNow https://t.co/mCS9B4Flgl
David Liew @drdavidliew ( View Tweet )
2 months 3 weeks ago
Leflunomide - a perennial question in GCA, that we still haven’t answered (as this meta-analysis shows), despite clear potential.
We are getting a clearer idea of the strengths/limitations of MTX in GCA, is it now time to get better clarity for LEF?
#ACR25 ABST0731 @RheumNow https://t.co/ycuvPx8Xdg
David Liew @drdavidliew ( View Tweet )
2 months 3 weeks ago
Even when inflammation is quiet, fatigue often lingers. In 246 RA pts, 43% had significant fatigue—closely tied to PROMs, not labs. RAPID3 < 6 flagged the few truly “fatigue-free.”
Don’t overlook the VAS_Fatigue—it tells a real story.
@RheumNow #ACR25 Abstract# 0380
Jiha Lee @JihaRheum ( View Tweet )
2 months 3 weeks ago
Retrospective study by Dr. Goudot et al. - pts w/D2T PsA had dactylitis, fibromylagia & ischemic cardiomyopathy
In multivariate analysis, FM & ischemic CM found to be RFs for D2T PsA
☝️Consider other dx if D2T PsA
#ACR25 @RheumNow ABS0566 https://t.co/FOXv6LbysZ
sheila @RHEUMarampa ( View Tweet )
2 months 3 weeks ago
Using ChatGPT to diagnose axSpA, in 10 low back pain cases, it outperformed clinicians in diagnostic precision (75% vs. 60%) and sensitivity (85% vs. 80%), completing the task 5x faster. Specialty framing (e.g., Rheum vs Neuro) didn’t affect accuracy. Abstract 0530 @RheumNow https://t.co/YMMC4XIX9m
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
2 months 3 weeks ago
After propensity matching, this retrospective cohort study showed that #lupus nephritis patients on GLP-1 agonists had ⬇️ CKD progression, mortality & AMI risk vs. LN pts on SGLT2is.
Interesting data but what could explain it? Further studies are needed
#ACR25 @RheumNow Abs0841 https://t.co/FtsGbMDcCv
sheila @RHEUMarampa ( View Tweet )
2 months 3 weeks ago
#ACR25 Abstr#645. Dapirolizumab, anti-CD40L-i met primary endpoint, BICLA in Phase 3 RCT non-renal SLE. Key secondary endpoints showed higher rates of & time in LLDAS and remission in DAP vs PBO. Meaningful targets re: damage accrual & better longterm outcomes @RheumNow https://t.co/IxesXhi34R
Links:
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 months 3 weeks ago
#ACR25 Abstr#641 Phase 1/2 CASTLE Basket Trial fully recruited N=24 (10 SLE, 9 SSc, 5 IIM). Short-term data of autologous CD19-CAR T
Zorpocabtagene-autoleucel/MB19.1:
- 22/24 high degree efficacy
- no relapse
- no high grade CRS/ICANS
*Need larger Phase prior approval @RheumNow https://t.co/sp1nieeCvl
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 months 3 weeks ago
Real-world JAK persistence in RA is low: <30% at 2 years across Medicare & Marketscan data (n≈20K). Baricitinib lowest persistence; TOF & UPA slightly higher. Oral convenience hasn’t solved long-term adherence. Why? Safety, cost, access?
@RheumNow #ACR25 A#0369
Jiha Lee @JihaRheum ( View Tweet )
2 months 3 weeks ago
Project from my group & rheum-bound resident Mary Peng!
As expected, ischemic vision loss for GCA compared to PMR (HR 5.4) and gen pop (HR 5.6) 😬
NO difference for PMR vs gen pop (aHR 1.10, 95% CI 0.86–1.41)
Reassuring for pts w/PMR!
#ACR25 @RheumNow Abstr#0753 #ACRBest https://t.co/HKzc7OOzmP
Mike Putman @EBRheum ( View Tweet )
2 months 3 weeks ago
Only 32% of RA pts were satisfied with current txs. In a discrete choice experiment of 354 US pts, many preferred a vagus nerve stimulator over another biologic/JAKi, especially those with prior tx failures. Cost, function, and fatigue drove preferences.
@RheumNow #ACR25 A#0370
Jiha Lee @JihaRheum ( View Tweet )
2 months 3 weeks ago
